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A randomized, double blind, sham-controlled trial proved
the efficacy and safety of external trigeminal nerve stim-
ulation (e-TNS) with the Cefaly device (CEFALY
Technology, Belgium) for the preventive treatment of
episodic migraine [1]. Safety and patients’ satisfaction
were confirmed by a retrospective survey of 2313 users [2].
Although many patients also report benefit from using
the device during migraine attacks, only limited data is
available on the efficiency of Cefaly for attack treatment.
In a pilot trial of ten episodic migraine patients who treated
three attacks with the device [3], total relief without rescue
medication was reported in 12% of attacks, incomplete
relief with rescue medication in 42.5% and no effect in
45.5%. In an open study including 16 patients, the Cefaly
device was effective and well tolerated as rescue therapy
for migraine attack symptoms present since at least 72 h
and reduced the headache on average by 46% [4].
While awaiting the results of larger controlled trials,
useful information might be obtained by interviewing
migraineurs who apply the device for migraine prevention
about its use during attacks and ability to reduce acute anti-
migraine drug intake. We conducted, therefore, a survey on
807 Belgian, Swiss and French subjects from the Cefaly
customer database who were identified as regular users
because they had purchased the device and ordered new
electrodes within the last year. One of us (JS) invited them
by email to answer on-line an eight-item questionnaire,
using the SurveyMonkey [5] service provider to implement
the survey and collect the results. Confidentiality was
guaranteed by fully disabling the electronic and IP
addresses recordings in order to collect anonymous
responses.
Among 463 subjects who filled in the questionnaire
(57% responder rate), 413 (89.2%) who answered ‘‘yes’’ to
the first question ‘‘You suffer from headaches. Has a
physician diagnosed them as typical migraine?’’ were
invited to proceed to the following questions and included
in the analyses (Fig. 1). The questionnaire was designed to
retrieve the following information: monthly attack fre-
quency, use of Cefaly during an attack or reasons for non-
using it, proportion of attacks treated with Cefaly, pro-
portion of Cefaly-treated attacks with reduction of acute
anti-migraine drug intake, class of drugs with reduced
intake.
The primary outcome measure was the mean number of
acute anti-migraine drug intake avoided per month per
patient thanks to the use of Cefaly. Secondary outcome
measures were: percentage of subjects using the device
during an attack, percentage of attacks treated with the
device, percentage of Cefaly-treated attacks with reduc-
tion of acute anti-migraine drugs.
The results are displayed in Table 1. Among the 413
regular device users for prevention, 88.6% also used it as
an acute treatment in 71.8% of their attacks. In 42.6% of
these attacks the use of Cefaly was accompanied by
reduced intake of acute anti-migraine medications. For the
total cohort, Cefaly allowed to reduce acute migraine
drug intake on average in 2.93 attacks per month per
subject. If only those 366 subjects using the device for
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attack treatment are considered, this number increases to
3.31 attacks per month per subject. This represents the
lower bound of the actual numerical reduction in drug
intake, since for one attack multiple intakes can occur.
Half of subjects who did not use the Cefaly during an
attack claimed this was due to a lack of efficacy; 23.4% did
not use it for practical reasons and only 14.9% because of
unbearable sensations due to the electrical stimulation.
All respondents were regular Cefaly users and the
survey was thus biased towards subjects who were globally
satisfied with the device. However, subjects were not
informed beforehand that the focus of the survey was on
attack treatment.
Clinical practice indicates that many migraine patients
who purchased the Cefaly also use it during attacks, but
that 88.6% of them would do so was not expected. This
may be due to the user manual that recommends program 1
for attack treatment, besides program 2 for prevention.
According to our survey, program 1 allows reducing
specific and non-specific acute migraine drug consumption
in 42.6% of attacks in more than 80% of subjects.
Admittedly, this is not a direct measure of the effect of
Cefaly on migraine attacks, but the high proportion of
ictal users and attacks treated per subject (71.8%) suggests
that the device is consistently beneficial. Moreover, the
reduction of acute medication intake of 3.31 per subject per
month has pharmaco-economic importance and reduces the
chronifying risk of medication overuse in patients with
frequent migraine.
Taken together, this survey suggests that e-TNS with
Cefaly (program 1) may mitigate migraine attacks in
subjects using regularly the device for prevention, as it is
able to reduce intake of acute migraine drugs. It also
indicates that Cefaly is well tolerated during an attack by
Fig. 1 Flow chart of the study protocol
Table 1 Study results
Migraine frequency
Average number of monthly migraine attacks 9.47
Primary outcome measure
Mean number of acute anti-migraine drugs avoided per month per subject (lower bound)
Total population (n = 413) 2.93
Attack users (n = 366) 3.31
Secondary outcome measures
Percentage of subjects using the device to treat attacks 88.6%
Percentage of attacks treated with the device 71.8%
Percentage of Cefaly-treated attacks for which acute anti-migraine drug intake is reduced 42.6%
Other results




Percentage of subjects unable to reduce acute medication intake in any of their attacks 18.3%
Reasons for not using Cefaly to treat migraine attacks
I cannot bear the feeling during an attack 14.9%
It does not provide sufficient relief 48.9%
I never tried 10.6%




the majority of subjects. These results need to be confirmed
in a randomized, controlled trial.
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